News

A novel therapeutic approach which exploits the normal biological process of gene silencing, or RNA interference (RNAi), is continuing to show promise as a potential treatment for hereditary ATTR (hATTR) amyloidosis. Results presented recently at the 1st European ATTR Amyloidosis...

Dr. Mazen Hanna is a cardiologist and current co-director of the Amyloidosis Program at the Cleveland Clinic alongside hematologist, Dr. Jason Valent. He has been a member of the heart failure and cardiac transplant unit in the department of cardiovascular...

The Northern California Amyloidosis Support Group which meets quarterly every year, held their 14th annual anniversary meeting in July in South San Francisco.  The event was hosted by the team at Prothena and was a very successful Patient’s Day event...

A survey of patients with all forms of cardiac amyloidosis and their caregivers was conducted in order to understand delays, errors, and inconsistencies in the diagnostic pathway for patients with cardiac amyloidosis and validated using caregiver responses. Data from AL...

Dr. Scott Gottlieb was appointed the new commissioner of the Food and Drug Administration (FDA) on May 11, 2017. He is a physician and a cancer survivor, having been successfully treated for Hodgkin’s lymphoma. Gottlieb has previously commented that the...